Soy isoflavone tablets do not appear to be associated with a reduction in bone loss or menopausal symptoms in women within the first five years of menopause.
Soy-derived products have been proposed to provide comparable benefits to estrogens but without the risks.
But over a two year period, no significant differences were found between women took soy isoflavone and those in a control group.
Read more at JAMA